| scholarly article | Q13442814 |
| P50 | author | Robin L McCarley | Q42365326 |
| P2093 | author name string | Suraj U Hettiarachchi | |
| Maria F Mendoza | |||
| Nicole M Hollabaugh | |||
| P2860 | cites work | The three-dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction | Q24561980 |
| Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release | Q24679998 | ||
| Crystal structure of human DT-diaphorase: a model for interaction with the cytotoxic prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) | Q27620114 | ||
| Structure-based development of anticancer drugs: complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinones | Q27635195 | ||
| Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches | Q27636626 | ||
| Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1) | Q27658027 | ||
| Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells | Q28206214 | ||
| DT-diaphorase-catalysed reduction of 1,4-naphthoquinone derivatives and glutathionyl-quinone conjugates. Effect of substituents on autoxidation rates | Q28340699 | ||
| Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking | Q30822076 | ||
| Studies on the DT-diaphorase-catalysed reaction employing quinones as substrates: evidence for a covalent modification of DT-diaphorase by tetrachloro-p-benzoquinone | Q31036096 | ||
| The computer program LUDI: a new method for the de novo design of enzyme inhibitors | Q33214112 | ||
| Elusive transition state of alcohol dehydrogenase unveiled | Q34006607 | ||
| Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors | Q34319102 | ||
| The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure | Q34326042 | ||
| Enzyme-activated targeting of liposomes | Q34463643 | ||
| One- and two-electron reduction of quinones by rat liver subcellular fractions | Q34725484 | ||
| Biophysical mechanisms of phospholipase A2 activation and their use in liposome-based drug delivery | Q34980678 | ||
| Release of liposomal contents by cell-secreted matrix metalloproteinase-9 | Q35636788 | ||
| Enzyme-catalyzed activation of anticancer prodrugs | Q35682909 | ||
| Structure and mechanism of NAD[P]H:quinone acceptor oxidoreductases (NQO). | Q35718381 | ||
| Structure-activity relationships in two-electron reduction of quinones. | Q35718442 | ||
| DT-diaphorase: a target for new anticancer drugs | Q35832105 | ||
| Quinone reductases multitasking in the metabolic world | Q35956182 | ||
| Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. | Q36062352 | ||
| gem-disubstituent effect: theoretical basis and synthetic applications | Q36122564 | ||
| Antitumour quinones | Q36126795 | ||
| Quinone bioreductive prodrugs as delivery agents | Q36320749 | ||
| 6 Statistical analysis of enzyme kinetic data | Q36541244 | ||
| Flavin-dependent quinone reductases | Q36972450 | ||
| Redox-triggered contents release from liposomes. | Q36990677 | ||
| Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential | Q37080932 | ||
| Design of anticancer prodrugs for reductive activation. | Q37238437 | ||
| Design of self-immolative linkers for tumour-activated prodrug therapy | Q37239063 | ||
| Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, rat, human, and mouse-rat chimeric enzymes | Q38295863 | ||
| Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. | Q38468906 | ||
| COMPARE analysis of the toxicity of an iminoquinone derivative of the imidazo[5,4-f]benzimidazoles with NAD(P)H:quinone oxidoreductase 1 (NQO1) activity and computational docking of quinones as NQO1 substrates. | Q39361253 | ||
| Shedding light by cancer redox-human NAD(P)H:quinone oxidoreductase 1 activation of a cloaked fluorescent dye. | Q39472115 | ||
| Triazoloacridin-6-ones as novel inhibitors of the quinone oxidoreductases NQO1 and NQO2. | Q39758665 | ||
| Lavendamycin antitumor agents: structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies | Q39985328 | ||
| Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1 targeted tripartite quinone drug delivery system. | Q40033890 | ||
| Indolequinone antitumour agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase. | Q40119450 | ||
| Synthesis of bioreductive esters from fungal compounds | Q40125539 | ||
| Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells | Q40141760 | ||
| Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1). | Q40577262 | ||
| The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase | Q40748429 | ||
| Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4, 7-dione] prop-beta-en-alpha-ol (EO9) by human DT-diaphorase | Q41145264 | ||
| Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. | Q41218087 | ||
| Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines | Q41305126 | ||
| Molecular characterization of binding of substrates and inhibitors to DT-diaphorase: combined approach involving site-directed mutagenesis, inhibitor-binding analysis, and computer modeling | Q41681471 | ||
| A Model for NAD(P)H:Quinoneoxidoreductase 1 (NQO1) Targeted Individualized Cancer Chemotherapy. | Q42003731 | ||
| Identification of a class 3 aldehyde dehydrogenase in human saliva and increased levels of this enzyme, glutathione S-transferases, and DT-diaphorase in the saliva of subjects who continually ingest large quantities of coffee or broccoli. | Q42464014 | ||
| Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse | Q43453424 | ||
| Mechanism of NAD(P)H:quinone reductase: Ab initio studies of reduced flavin | Q43599714 | ||
| Indolequinone antitumor agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase. Part 2. | Q43742640 | ||
| A comprehensive study of the active site residues of DT-diaphorase: rational design of benzimidazolediones as DT-diaphorase substrates | Q43907767 | ||
| Two-electron reduction of quinones by rat liver NAD(P)H:quinone oxidoreductase: quantitative structure-activity relationships. | Q44082365 | ||
| LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads | Q44114180 | ||
| Kinetic and docking studies of the interaction of quinones with the quinone reductase active site | Q44318486 | ||
| H and other transfers in enzymes and in solution: theory and computations, a unified view. 2. Applications to experiment and computations. | Q45952580 | ||
| Matrix metalloproteinase-assisted triggered release of liposomal contents | Q46851804 | ||
| Fast calculation of van der Waals volume as a sum of atomic and bond contributions and its application to drug compounds | Q47632144 | ||
| The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol. | Q50479449 | ||
| New latent fluorophore for DT diaphorase. | Q51289130 | ||
| Docking of hydrophobic ligands with interaction-based matching algorithms. | Q51646570 | ||
| Multiple automatic base selection: protein-ligand docking based on incremental construction without manual intervention. | Q52260133 | ||
| CASP2 experiences with docking flexible ligands using FlexX. | Q52281039 | ||
| A fast flexible docking method using an incremental construction algorithm. | Q52298930 | ||
| Placement of medium-sized molecular fragments into active sites of proteins. | Q52311354 | ||
| Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships. | Q52536584 | ||
| Soy induces phase II enzymes but does not inhibit dimethylbenz[a]anthracene-induced carcinogenesis in female rats. | Q53418680 | ||
| Mechanism of NAD(P)H:Quinone reductase: Ab initio studies of reduced flavin | Q57206145 | ||
| Synthesis and evaluation of prodrugs for anti-angiogenic pyrrolylmethylidenyl oxindoles | Q57932233 | ||
| Indolequinone Antitumor Agents: Correlation between Quinone Structure, Rate of Metabolism by Recombinant Human NAD(P)H:Quinone Oxidoreductase, and in Vitro Cytotoxicity1 | Q60407932 | ||
| In silico identification and biochemical characterization of novel inhibitors of NQO1 | Q61781930 | ||
| High levels of expression of the NAD(P)H:Quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin | Q68249518 | ||
| DT-diaphorase: purification, properties, and function | Q68592259 | ||
| One-electron-transfer reactions in biochemical systems. V. Difference in the mechanism of quinone reduction by the NADH dehydrogenase and the NAD(P)H dehydrogenase (DT-diaphorase) | Q68752049 | ||
| Stereopopulation control. I. Rate enhancement in the lactonizations of o-hydroxyhydrocinnamic acids | Q69395251 | ||
| Active site studies of DT-diaphorase employing artificial flavins | Q71672997 | ||
| Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues | Q73086605 | ||
| Drug delivery by phospholipase A(2) degradable liposomes | Q73701620 | ||
| Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors | Q77332679 | ||
| Cholesterol phosphate derivatives: synthesis and incorporation into a phosphatase and calcium-sensitive triggered release liposome | Q77552031 | ||
| Protective role of ubiquinone in vitamin E and selenium-deficient plasma membranes | Q78027972 | ||
| Secreted phospholipase A(2) as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue | Q78733783 | ||
| NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism | Q79856195 | ||
| P433 | issue | 40 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 8014-8026 | |
| P577 | publication date | 2012-09-28 | |
| P1433 | published in | Biochemistry | Q764876 |
| P1476 | title | Human NAD(P)H:quinone oxidoreductase type I (hNQO1) activation of quinone propionic acid trigger groups | |
| P478 | volume | 51 |
| Q38714686 | A Near-Infrared, Wavelength-Shiftable, Turn-on Fluorescent Probe for the Detection and Imaging of Cancer Tumor Cells. |
| Q51301248 | An NAD(P)H:quinone oxidoreductase 1 (NQO1) enzyme responsive nanocarrier based on mesoporous silica nanoparticles for tumor targeted drug delivery in vitro and in vivo. |
| Q60931062 | Cancer-Specific Biomarker hNQO1-Activatable Fluorescent Probe for Imaging Cancer Cells In Vitro and In Vivo |
| Q92691089 | Characterization of a highly specific NQO1-activated near-infrared fluorescent probe and its application for in vivo tumor imaging |
| Q48232132 | Combined molecular modelling and 3D-QSAR study for understanding the inhibition of NQO1 by heterocyclic quinone derivatives |
| Q33715905 | Detection and cellular imaging of human cancer enzyme using a turn-on, wavelength-shiftable, self-immolative profluorophore. |
| Q36230143 | Efficacious fluorescence turn-on probe for high-contrast imaging of human cells overexpressing quinone reductase activity. |
| Q58694676 | Hypoxia-activated prodrugs and redox-responsive nanocarriers |
| Q90164338 | Kinetics of Flavoenzyme-Catalyzed Reduction of Tirapazamine Derivatives: Implications for Their Prooxidant Cytotoxicity |
| Q58374433 | Mitochondria-targeted aggregation induced emission theranostics: crucial importance of activation |
| Q36232485 | Novel Redox-Responsive Amphiphilic Copolymer Micelles for Drug Delivery: Synthesis and Characterization |
| Q36435743 | Profluorogenic reductase substrate for rapid, selective, and sensitive visualization and detection of human cancer cells that overexpress NQO1 |
| Q39018895 | Self-immolative bioluminogenic quinone luciferins for NAD(P)H assays and reducing capacity-based cell viability assays |
| Q49182019 | Siderophore-fluoroquinolone conjugates containing potential reduction-triggered linkers for drug release: synthesis and antibacterial activity. |
| Q39136162 | Stimuli-responsive liposomes for drug delivery |
Search more.